engleski

Is the long-term thyroxine treatment risk for bone mass loss?

In this prospective study, the effect of suppressive therapy with levothyroxine after total surgical thyreoidectomy for diferentiated thyroid carcinoma was investigated. There were 17 premenopausal women with regular menstruations, and 11 men, aged less than 50 years. None of the patients had bone metastases or other distal organs. Bone mineral density was measured on two occasions during a four-year period. A DPX operating on principle of dual-energy X-ray absorptiometry, was used for the measurement of the lumbar spine and the femoral neck bone mineral content. Mineral density in the lower third of the forearm was determined on a Lunar SP2, operating on the principle of single-photon absorptiometry. Bone loss was found in 10 women and 4 male subjects. Long-term suppressive thyroxine therapy is associated with the risk of bone mass loss in some patients.

bone densitometry; thyroxine suppressive therapy; bone loss

nije evidentirano